PBI-4050 sodium

Research use only, not for human use.

PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively.

PBI-4050 (Setogepram, PBI4050) is a synthetic analog of a medium-chain fatty acid that displays agonist and antagonist ligand affinity toward GPR40 and GPR84, respectively; PBI-4050 significantly attenuated fibrosis in many injury contexts, as evidenced by the antifibrotic activity observed in kidney, liver, heart, lung, pancreas, and skin fibrosis models; PBI-4050 is a first-in-class compound that may be effective for managing inflammatory and fibrosis-related diseases.Fibrosis Phase 2 Clinical.

Inhibited TGF-β-activated HSC proliferation. TGF-β (10 ng/mL) increased HSC proliferation by 10%.Cell Cycle Analysis Cell Line:HSCs Concentration:250 μM, 500 μM Incubation Time:24 hours Result:Inhibited cell cycle progression.

Animal Model:Type 2 diabetes eNOS-/-db/db mice Dosage:100 mg/kg/day Administration:Given via daily gavage from 8-20 weeks Result:Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved.

Setogepram sodium

GPCR/G Protein

FFAR

FFAR

Other Indications

Fibrosis

1254472-97-3

229.275

C13H18NaO2

>98% (HPLC)

H2O : ≥ 100 mg/mL438.10 m; MDMSO : ≥ 64 mg/mL280.38 mM

CCCCCC1=CC(=CC=C1)CC(=O)[O-].[Na+]

2-(3-pentylphenyl)acetic acid, sodium salt

(-20℃)

With Ice Pack

≥ 2 years